Recent research reported that PPAR ligands were shown to upregulate the expression of human organic cation transporter type 1(hOCT1), leading to an increase in imatinib (the gold standard for the treatment of chronic myeloid leukemia) uptake [43], resulted in inhibiting cell growth and inducing differentiation and apoptosis. This evidence concerns the gene SLC22A1 and chronic myelogenous leukemia, BCR-ABL1 positive.